Supernus Pharmaceuticals Inc’s filing revealed that its Sr. VP of IP, CSO Bhatt Padmanabh P. unloaded Company’s shares for reported $0.51 million on Mar 21 ’24. In the deal valued at $35.31 per share,14,491 shares were sold. As a result of this transaction, Bhatt Padmanabh P. now holds 8,570 shares worth roughly $0.27 million.
Then, Bhatt Padmanabh P. sold 400 shares, generating $14,124 in total proceeds. Upon selling the shares at $35.31, the Sr. VP of IP, CSO now owns 8,570 shares.
Before that, Bhatt Padmanabh P. sold 12,364 shares. Supernus Pharmaceuticals Inc shares valued at $436,573 were divested by the Sr. VP of IP, CSO at a price of $35.31 per share. As a result of the transaction, Bhatt Padmanabh P. now holds 8,570 shares, worth roughly $0.27 million.
Jefferies also remained covering SUPN and has increased its forecast on April 13, 2021 with a “Buy” recommendation from previously “Hold” rating. Piper Sandler revised its rating on June 16, 2020. It rated SUPN as “an Overweight” which previously was an “a Neutral”.
Price Performance Review of SUPN
On Monday, Supernus Pharmaceuticals Inc [NASDAQ:SUPN] saw its stock fall -6.32% to $31.43. Over the last five days, the stock has lost -6.24%. Supernus Pharmaceuticals Inc shares have risen nearly 8.60% since the year began. Nevertheless, the stocks have fallen -12.38% over the past one year. While a 52-week high of $39.09 was reached on 03/21/24, a 52-week low of $21.99 was recorded on 02/28/24. SMA at 50 days reached $30.79, while 200 days put it at $29.10. A total of 0.79 million shares were traded, compared to the trading of 0.31 million shares in the previous session.
Levels Of Support And Resistance For SUPN Stock
The 24-hour chart illustrates a support level at 30.31, which if violated will result in even more drops to 29.18. On the upside, there is a resistance level at 32.83. A further resistance level may holdings at 34.22. The Relative Strength Index (RSI) on the 14-day chart is 44.41, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.94, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 82.51%. Stochastics %K at 29.22% indicates the stock is a holding.
How much short interest is there in Supernus Pharmaceuticals Inc?
A steep rise in short interest was recorded in Supernus Pharmaceuticals Inc stocks on Mar 15, 2024, growing by 0.89 million shares to a total of 4.92 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 4.03 million shares. There was a rise of 18.09%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 13.55% of the overall stock float, the days-to-cover ratio (short ratio) rose to 10.54.
